/IXHL
IXHL Stock - Incannex Healthcare Limited
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.44+10.27%
+$0.04 (+10.27%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.61
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.16
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.48
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IXHL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.43 – $0.44
TARGET (TP)$0.50
STOP LOSS$0.40
RISK/REWARD1:1.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.60
52W High$2.25
52W Low$0.08
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $86,000 | $17,965.2 | N/A | N/A | $1.43M |
| Gross Profit | $86,000 | $17,965.2 | N/A | $-4,359 | $740,538 |
| Gross Margin | 100.0% | 100.0% | N/A | N/A | 51.9% |
| Operating Income | $-23,789,000 | $-44,974,381 | $-13,638,000 | $-10,164,241 | $-8,573,546 |
| Net Income | $-46,885,000 | $-27,634,968 | $-48,811,000 | $-10,252,537 | $-8,544,809 |
| Net Margin | -54517.4% | -153825.0% | N/A | N/A | -599.3% |
| EPS | $-1.36 | $-1.14 | $-3.17 | $-0.03 | $-0.03 |
Company Overview
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IXHLBeat Rate
67%
Last 3 quarters
Avg Surprise
+20.7%
EPS vs Estimate
Beats / Misses
2/1
Last 12 quarters
Latest EPS
$-0.39
Q3 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
+48.7%
$-0.39vs$-0.76
Q4 24
No data
Q2 25
+47.8%
$-0.24vs$-0.46
Q2 25
No data
Q3 25
-34.5%
$-0.39vs$-0.29
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 13, 2026 | $-0.02 | — | — | — |
Q3 2025 | Sep 29, 2025 | $-0.29 | $-0.39 | -34.5% | ✗ MISS |
Q2 2025 | May 15, 2025 | — | $-0.21 | — | — |
Q2 2025 | May 15, 2025 | $-0.46 | $-0.24 | +47.8% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | — | $-0.31 | — | — |
Q3 2024 | Sep 30, 2024 | $-0.76 | $-0.39 | +48.7% | ✓ BEAT |
Q2 2024 | May 15, 2024 | — | $-0.38 | — | — |
Q1 2024 | Mar 1, 2024 | — | $-0.33 | — | — |
Q4 2023 | Dec 1, 2023 | — | $2.01 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-0.05 | — | — |
Q1 2023 | Mar 30, 2023 | — | $-0.22 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.19 | — | — |
Q4 2022 | Oct 28, 2022 | — | $-0.01 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.89 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.01 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.01 | — | — |
Latest News
Incannex Healthcare shares are trading higher after the company announced the FDA granted Fast Track designation for IHL-42X.
📈 PositiveBenzinga•Dec 3, 2025, 01:11 PM
Incannex Healthcare Secures FDA Fast Track Designation For IHL-42X in Obstructive Sleep Apnea
📈 PositiveBenzinga•Dec 3, 2025, 01:09 PM
Incannex Healthcare shares are trading higher after the company announced Phase 2 results for IHL-42X and PSX-001.
📈 PositiveBenzinga•Oct 30, 2025, 01:16 PM
Incannex Healthcare Releases Phase 2 Results For IHL-42x, Showing Up To An 83% Reduction In Sleep Apnea Severity With Strong Safety And Patient-Reported Outcomes, And For PSX-001, Demonstrating Statistically Significant And Durable Improvements In Generalized Anxiety Disorder With Excellent Tolerability
📈 PositiveBenzinga•Oct 30, 2025, 12:04 PM
IXHL stock has given up its prior gain. Incannex Healthcare shares were trading higher after the company anounced an 180-day extension from the Nasdaq to regain compliance.
➖ NeutralBenzinga•Oct 22, 2025, 05:27 PM
Incannex Healthcare shares are trading higher after the company anounced an 180-day extension from the Nasdaq to regain compliance.
📈 PositiveBenzinga•Oct 22, 2025, 02:00 PM
Incannex granted extension by Nasdaq to regain compliance with minimum bid price requirement
➖ NeutralSeeking Alpha•Oct 22, 2025, 12:37 PM
Incannex Healthcare Receives 180-Day Extension From Nasdaq Until April 20, 2026 To Regain Compliance With The Minimum $1.00 Bid Price Requirement
➖ NeutralBenzinga•Oct 22, 2025, 12:07 PM
Incannex Healthcare shares are trading higher after the company announced results from its Phase 2 clinical trial of PSX-001.
📈 PositiveBenzinga•Aug 26, 2025, 12:46 PM
Incannex Reports Results For Phase 2 Clinical Trial Of PSX-001
📈 PositiveBenzinga•Aug 26, 2025, 12:01 PM
Incannex Healthcare shares rise more than 30% on $20M share repurchase program
📈 PositiveSeeking Alpha•Aug 22, 2025, 12:12 PM
Incannex Healthcare shares are trading higher after the company authorized a $20M share repurchase program.
📈 PositiveBenzinga•Aug 22, 2025, 12:03 PM
Incannex Healthcare Board Authorizes Share Repurchase Program For Up To $20M
📈 PositiveBenzinga•Aug 22, 2025, 12:02 PM
Frequently Asked Questions about IXHL
What is IXHL's current stock price?
Incannex Healthcare Limited (IXHL) is currently trading at $0.44 per share. The stock has moved +10.27% today.
What is the analyst price target for IXHL?
No analyst price targets are currently available for this stock.
What sector is Incannex Healthcare Limited in?
Incannex Healthcare Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is IXHL's market cap?
Incannex Healthcare Limited has a market capitalization of $0.02 billion, making it a small-cap company.
Does IXHL pay dividends?
No, Incannex Healthcare Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
CGTX
Cognition Therapeutics, Inc.
$1.54
Mkt Cap: $0.1B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
LUCD
Lucid Diagnostics Inc.
$1.12
Mkt Cap: $0.1B
SCLX
Scilex Holding Company
$14.35
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
STSS
Sharps Technology, Inc.
$2.22
Mkt Cap: $0.1B
SXTC
China SXT Pharmaceuticals, Inc.
$1.61
Mkt Cap: $0.2B
TTRX
Turn Therapeutics Inc.
$3.00
Mkt Cap: $0.1B
ZYBT
Zhengye Biotechnology Holding Limited
$1.85
Mkt Cap: $0.1B
Explore stocks similar to IXHL for comparison